Amazon Storefront: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Socials:

Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/hunterwilliamscoaching/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Video Topic Request: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamsvideotopic.carrd.co/⁠⁠⁠⁠⁠

Today I'm breaking down something that's been blowing up in the peptide world. The FDA just made a major announcement about moving 19 popular peptides from Category 2 to Category 1. And I want to share my honest thoughts on what this actually means for you.

First I walk through how we got here. The Biden administration's original scheduling decision. The rise of the research peptide market. And why roughly four out of five peptides consumed in the US today come from research companies.

Then I get into what the FDA is actually proposing. The July hearing. The February 2027 timeline. And what Category 1 status would mean for compounding pharmacies and telehealth clinics.

But here's where it gets interesting. I share my prediction on where prices are headed and why I think we'll eventually see price parity between prescribed and research peptides. I also dig into what I think is a quiet quid pro quo happening between Big Pharma and the FDA around GLP-1s.

This is speculation on my part. I'm not a doctor or a lawyer. But I wanted to give you my honest read on where this is all going. Let me know your thoughts in the comments.

Timestamps

00:00 — Intro and disclaimers (not a doctor, not a lawyer)
01:40 — History: How the Biden FDA scheduled 19 peptides as Category 2
02:44 — The rise of the research peptide gray market (4 out of 5 peptides)
04:18 — RFK on Joe Rogan and the FDA's Category 1 plans
04:58 — What Category 1 actually means (Sermorelin example)
05:42 — The July hearing and February 2027 final say timeline
07:18 — FDA cracking down on GLP-1s from research companies
08:42 — More compounding pharmacies and telehealth clinics entering the space
09:08 — The Metformin analogy and future price parity
13:20 — The rug pull theory: FDA and Big Pharma quid pro quo on GLP-1s
14:04 — Why Eli Lilly is protecting retatrutide (projected $50B/year product)
17:04 — Final thoughts and the golden age of peptides